464: Is Obesity Associated with more Aggressive Prostate Cancer? (Data from Capsure)

2004 ◽  
Vol 171 (4S) ◽  
pp. 124-124 ◽  
Author(s):  
Christopher J. Kane ◽  
William W. Bassett ◽  
Natalia Sadetsky ◽  
Stephanie J. Silva ◽  
David J. Pasta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Aggressive Prostate Cancer ◽  
Cancer Data

1414: Aggressive Prostate Cancer is Associated with Nucleotide Variants of the Semaphorin 3F Gene

2005 ◽  
Vol 173 (4S) ◽  
pp. 383-383
Author(s):  
Susan L. Naylor ◽  
Xin He ◽  
RuiHua Xiang ◽  
Dawn K. Garcia ◽  
Edith D. Canby-Hagino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Aggressive Prostate Cancer ◽  
Semaphorin 3F

scholarly journals Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1495
Author(s):  
Tú Nguyen-Dumont ◽  
James G. Dowty ◽  
Robert J. MacInnis ◽  
Jason A. Steen ◽  
Moeen Riaz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Prediction ◽  
Prediction Models ◽  
Risk Prediction Models ◽  
Aggressive Prostate Cancer ◽  
Panel Testing ◽  
Pathogenic Variants ◽  
Increased Risk ◽  
Predisposition Genes ◽  
Rare Genetic Variants

While gene panel sequencing is becoming widely used for cancer risk prediction, its clinical utility with respect to predicting aggressive prostate cancer (PrCa) is limited by our current understanding of the genetic risk factors associated with predisposition to this potentially lethal disease phenotype. This study included 837 men diagnosed with aggressive PrCa and 7261 controls (unaffected men and men who did not meet criteria for aggressive PrCa). Rare germline pathogenic variants (including likely pathogenic variants) were identified by targeted sequencing of 26 known or putative cancer predisposition genes. We found that 85 (10%) men with aggressive PrCa and 265 (4%) controls carried a pathogenic variant (p < 0.0001). Aggressive PrCa odds ratios (ORs) were estimated using unconditional logistic regression. Increased risk of aggressive PrCa (OR (95% confidence interval)) was identified for pathogenic variants in BRCA2 (5.8 (2.7–12.4)), BRCA1 (5.5 (1.8–16.6)), and ATM (3.8 (1.6–9.1)). Our study provides further evidence that rare germline pathogenic variants in these genes are associated with increased risk of this aggressive, clinically relevant subset of PrCa. These rare genetic variants could be incorporated into risk prediction models to improve their precision to identify men at highest risk of aggressive prostate cancer and be used to identify men with newly diagnosed prostate cancer who require urgent treatment.

scholarly journals The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 875
Author(s):  
Kerri Beckmann ◽  
Hans Garmo ◽  
Ingela Franck Lissbrant ◽  
Pär Stattin
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Clinical Care ◽  
Prostate Cancer Risk ◽  
Real World Data ◽  
Level Of Evidence ◽  
World Data ◽  
Cancer Data ◽  
Using Data ◽  
Randomised Controlled

Real-world data (RWD), that is, data from sources other than controlled clinical trials, play an increasingly important role in medical research. The development of quality clinical registers, increasing access to administrative data sources, growing computing power and data linkage capacities have contributed to greater availability of RWD. Evidence derived from RWD increases our understanding of prostate cancer (PCa) aetiology, natural history and effective management. While randomised controlled trials offer the best level of evidence for establishing the efficacy of medical interventions and making causal inferences, studies using RWD offer complementary evidence about the effectiveness, long-term outcomes and safety of interventions in real-world settings. RWD provide the only means of addressing questions about risk factors and exposures that cannot be “controlled”, or when assessing rare outcomes. This review provides examples of the value of RWD for generating evidence about PCa, focusing on studies using data from a quality clinical register, namely the National Prostate Cancer Register (NPCR) Sweden, with longitudinal data on advanced PCa in Patient-overview Prostate Cancer (PPC) and data linkages to other sources in Prostate Cancer data Base Sweden (PCBaSe).

PPARGC1A and ADIPOQ polymorphisms are associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity

2017 ◽  
Vol 19 (3) ◽  
pp. 297-303 ◽  
Author(s):  
Patricia Canto ◽  
Jesús Benítez Granados ◽  
Guillermo Feria-Bernal ◽  
Ramón Mauricio Coral-Vázquez ◽  
Eduardo García-García ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Aggressive Prostate Cancer ◽  
Mexican Mestizo ◽  
Overweight Or Obesity
Sign in / Sign up

Export Citation Format

Share Document